ProCE Banner Activity

Emerging HER2-Selective TKIs for HER2-Mutated NSCLC

Clinical Thought

Explore expert insights on the latest developments with HER2-selective TKIs for HER2-mutated NSCLC.

Released: November 12, 2024

Expiration: November 11, 2025

Share

Faculty

Misako Nagasaka

Misako Nagasaka, MD, PhD

Associate Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California Irvine School of Medicine
Orange, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure

Primary Author

Misako Nagasaka, MD, PhD

Associate Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California Irvine School of Medicine
Orange, California

Misako Nagasaka, MD, PhD: consultant/advisor/speaker: AstraZeneca, Blueprint Medicines, Caris Life Sciences, Daiichi Sankyo, EMD Serono, Genentech, Janssen, Lilly, Mirati, Novartis, Pfizer, Regeneron, Takeda; other financial or material support: AnHeart.